https://www.selleckchem.com/pr....oducts/iacs-13909.ht
3, deletion in Xq22.1, and deletion in 17p13.3) were identified. Conclusion These findings have implications for our understanding of the approach to genetic testing and counseling of patients affected with seizures and epilepsy disorders. The overall diagnostic yield of exome/genome sequencing in our cohort was 23%. The main characteristic is genetic heterogeneity, supporting NGS technology as a suitable testing approach for seizures and epilepsy disorders. Genetic counseling for newly identified disease-causing variants depends on